Skip to Content
Merck
CN
HomeMass SpectrometryAnalysis of Acylcarnitines in Dried Blood Spots (DBS) Samples by FIA-MS/MS

Analysis of Acylcarnitines in Dried Blood Spots (DBS) Samples by FIA-MS/MS

Arun Babu Kumar Ph.D.1, Sarah Aijaz Ph.D.1, Uma Sreenivasan Ph.D.1 Merck 1 Round Rock, TX, USA

Workflow

Extraction

Sample extraction and derivatization
Sample extraction and derivatization

    Analysis

    FIA-MS/MS Analysis
    FIA-MS/MS Analysis

      Detection

      Detection & Quantification
      Detection & Quantification

        1. Overview: FIA-MS/MS for Acylcarnitines Analysis in Dried Blood Spots (DBS)

        In the 1960s, Robert Guthrie implemented the large-scale use of dried blood spots (DBS) for the screening of newborns for Phenylketonuria (PKU). Since then, the use of DBS in diagnosis has expanded to include a variety of metabolic disorders and other ailments. Tandem mass spectrometry (MS/MS) has developed to be the choice of technique to analyze the DBS samples due to its sensitivity and capacity to multiplex to quantify several analytes simultaneously. MS/MS is widely used in clinical labs for the analysis of acylcarnitine panel in DBS to diagnose several fatty acid oxidation disorders and organic acid disorders.1-3 Flow injection analysis-MS/MS (FIA-MS/MS) is widely used in Tier-1 testing for identification and quantitation of acylcarnitines by direct quantitation against suitable internal standards. 4,5 Figure 1 below shows the overall workflow for the FIA-MS/MS analysis.

        Figure 1.Workflow for acylcarnitine analysis in dried blood spots (DBS) by FIA-MS/MS.

        Quantification of acylcarnitines using stable isotope-labeled (SIL) internal standards

        This article illustrates the utility of accurate and convenient stable isotope-labeled (SIL) internal standard solutions from Supelco for the analysis of acylcarnitine panel by FIA-MS/MS. The solution-based SIL internal standards are certified reference materials (CRMs), eliminating the need for quantitative transfer of lyophilized internal standards prior to dilution and provide accuracy and flexibility to prepare only the required amount of extraction solution with SIL internal standards.

        Acylcarnitine DBS reference samples from CDC were used as controls and two levels of control DBS samples from Recipe ClinChek with known concentrations for 13 acylcarnitines were used as samples for the analysis.

        2. Detailed Acylcarnitine FIA-MS/MS Workflow

        2.1 Acylcarnitine SIL Internal Standards

        Stable isotope-labeled (SIL) Acylcarnitine CRM solutions with 13 different heavy atom labeled acylcarnitines were used for the accurate quantification of different acylcarnitine species with the most closely related internal standard. Stable isotope-labeled CRMs in solution form offer greater flexibility, accuracy, homogeneity, and convenience in use than lyophilized materials. CRMs solution eliminates the need for quantitative transfer of lyophilized content for dilution to DBS extraction solution. Figure 2 shows the chemical structures, isotope labeling, and concentrations of the CRMs used as internal standards for the acylcarnitines analysis.

        Chemical structures of internal standards used for the acylcarnitines analysis.

        Figure 2.Chemical structures of internal standards used for the acylcarnitines analysis.

        2.2 Acylcarnitine Sample Extraction and Derivatization steps

        Table below shows the sequential steps involved in the extraction of acylcarnitines from DBS samples and derivatization into their butyl esters for enhanced sensitivity in the MS/MS.

        Extraction of DBS Punch

        Derivatization of DBS extract

        Figure 3. DBS sample extraction and derivatization steps

        2.3 DBS Extraction Solution Preparation

        The DBS extraction solution can be conveniently prepared by combining and diluting an appropriate amount of A-148-1ML, A-147-1ML, A-163 -1ML, A-181-1ML, and A-164-1ML in a volumetric flask with methanol (Figure 4). The concentrations of SIL acylcarnitines in the DBS extraction solution thus prepared are given in Table 1.

        Schematic of CRMs solution dilution by methanol in 250 mL volumetric flask

        Figure 4.Dilution schematic to prepare DBS extraction solution

        Table 1. Concentration of SIL acylcarnitines in DBS extraction solution

        2.4 Extraction and Derivatization of DBS punch

        Extraction steps of DBS punch is given below.

        The table below describes the steps involved in the Derivatization of DBS extract for enhanced sensitivity in MS.

        2.5 FIA-MS/MS conditions

        Experimental parameters for FIA-MS/MS:

        HPLC Gradient conditions:

        MS Source Parameters:

        2.6 Acquisition Parameters for Derivatized Acylcarnitines

        Table 2. MS/MS MRM acquisition parameters for each analyte and internal standards

        3. Acylcarnitine FIA-MS/MS Quantification and Results

        3.1 MRM Chromatogram of SIL Internal Standards

        MRM trace for butyl ester derivatized SIL acylcarnitines C0 d9, C10:0 d3, C12:0 d9, C14:0 d9, C16:0 d3, C18:0 d3, C2 d3 and C3 d3

        Figure 5.MRM trace for butyl ester derivatized SIL acylcarnitines C0 d9, C10:0 d3, C12:0 d9, C14:0 d9, C16:0 d3, C18:0 d3, C2 d3 and C3 d3

        MRM chromatograms for SIL acylcarnitines with peaks in flow injection

        Figure 6.MRM trace for butyl ester derivatized SIL acylcarnitines C4 d3, C5DC d3, C6 d3, C8:0 d3 and iC5 d9

        3.2 MRM Chromatogram of Blank and Control Injections

        Overlap chromatograms for all MRM transitions that include SIL internal standards and native acylcarnitines are shown in Figure 5. In the first overlapped MRM chromatogram, the control blank injection has a baseline signal for injection of methanol-water mixture. Whereas the second MRM overlap shows the injection of DBS extract from a CDS control sample.

        Blank (80:20 methanol/water) injections: Shows no background Interferences for all analytes and SIL Internal Standards

        Blank (80:20 methanol/water) injections: Shows no background Interferences for all analytes and SIL Internal Standards

        Chromatograms for all MRM transition with control blank injection and DBS extract from a CDS control

        Figure 7.MRM traces for all analytes and SIL internal standards with a blank injection of 80:20 methanol/water (top) and CDC Level-D DBS control (bottom)

        3.3 Quantification of Acylcarnitines and Interpretation of Results

        Acylcarnitine concentration is determined by comparing the MRM signal intensities against the know concentration of closely related SIL internal standards using the formula in the table below.

        Figure 8.Formula to calculate acylcarnitine concentration in DBS sample

        Accuracy was demonstrated through quantification of the four levels of control DBS samples from CDC with the known concentration of 20 acylcarnitines. The samples were analyzed (minimum of 3 replicate DBS extractions for each level) and the measured values were plotted against the actual mean concentrations of the control standards.6 As shown in Table 3, the correlation (slope) and R2 is close to 1 for all acylcarnitines, indicative of the good accuracy of the quantification. The correlations are shown graphically in Figures 9 and 10.

        In addition, two levels of control DBS samples from Recipe ClinChek with known concentration for 13 acylcarnitines were analyzed (in 6 replicate extractions for each level). As indicated in Table 4, the measured concentrations of all the acylcarnitines were within the expected control range.

        Evaluation of measured acylcarnitines concentration vs. actual concentration in CDC control DBS Samples

        Table 3. Correlation (slope) between the measured concentration and the actual mean concentration of acylcarnitines in DBS control standards from CDC

        Evaluation of measured acylcarnitines concentration vs. actual concentration in Recipe control DBS samples

        Table 4.Comparison of the average measured concentration of acylcarnitines against the expected concentration range in the Recipe ClinChek control DBS samples

        Correlation plots between measured and actual acylcarnitines concentration in CDC control DBS samples

        Correlation plot for the comparison of measured concentrations of acylcarnitines (C0, C2, C3, C3DC, C4, C4OH, C5:0, C5:1, C5DC) against the expected concentrations (MS/MS non-kit) in the four levels of CDC DBS controls

        Figure 9. Correlation plot for the comparison of measured concentrations of acylcarnitines (C0, C2, C3, C3DC, C4, C4OH, C5:0, C5:1, C5DC) against the expected concentrations (MS/MS non-kit) in the four levels of CDC DBS controls

        Correlation plot for the comparison of measured concentrations of acylcarnitines (C5OH, C6:0, C8:0, C10:0, C12:0, C14:0, C14:1, C16:0, C16OH, C18:0, C18OH) against the expected concentrations (MS/MS non-kit) in the four levels of CDC DBS controls

        Figure 10.Correlation plot for the comparison of measured concentrations of acylcarnitines (C5OH, C6:0, C8:0, C10:0, C12:0, C14:0, C14:1, C16:0, C16OH, C18:0, C18OH) against the expected concentrations (MS/MS non-kit) in the four levels of CDC DBS controls

        4. Conclusion: Quantitative Analysis of Acylcarnitines from Dried Blood Spots

        This study illustrates the use of stable isotope-labeled (SIL) Acylcarnitines Certified Reference Materials (CRM) for the quantitation of acylcarnitines in dried blood spots. FIA-MS/MS analysis in combination with the SIL Acylcarnitine CRM solutions from Supelco can be used effectively to accurately measure the concentration of different acylcarnitine species in dried blood spots (DBS). Due to the availability of a wide diversity of SIL acylcarnitine species from Supelco, the SIL Acylcarnitine CRM that is most chemically similar to the analyte could be chosen as the MS/MS reference for the utmost accurate quantification. The SIL CRMs in solutions offer greater flexibility, accuracy, homogeneity, and convenience than lyophilized materials. Solutions allow flexibility to prepare any volume of DBS extraction solution with the reference materials, as desired by the analyst. The CRMs in solution form eliminate the need for quantitative transfer of the lyophilized content for dilution to DBS Extraction Solution. A complete series of native Acylcarnitines Mix CRM solutions are also available from Supelco for instrument calibration, controls, and MS/MS tuning.

        Materials
        Loading

        References

        1.
        De Jesús VR, Chace DH, Lim TH, Mei JV, Hannon WH. 2010. Comparison of amino acids and acylcarnitines assay methods used in newborn screening assays by tandem mass spectrometry. Clinica Chimica Acta. 411(9-10):684-689. https://doi.org/10.1016/j.cca.2010.01.034
        2.
        Zytkovicz TH, Fitzgerald EF, Marsden D, Larson CA, Shih VE, Johnson DM, Strauss AW, Comeau AM, Eaton RB, Grady GF. 2001. Tandem Mass Spectrometric Analysis for Amino, Organic, and Fatty Acid Disorders in Newborn Dried Blood Spots. 47(11):1945-1955. https://doi.org/10.1093/clinchem/47.11.1945
        3.
        Chace DH, Lim T, Hansen CR, De Jesus VR, Hannon WH. 2009. Improved MS/MS analysis of succinylacetone extracted from dried blood spots when combined with amino acids and acylcarnitine butyl esters. Clinica Chimica Acta. 407(1-2):6-9. https://doi.org/10.1016/j.cca.2009.06.017
        4.
        Haynes CA, De Jesús VR. 2016. Simultaneous quantitation of hexacosanoyl lysophosphatidylcholine, amino acids, acylcarnitines, and succinylacetone during FIA?ESI?MS/MS analysis of dried blood spot extracts for newborn screening. Clinical Biochemistry. 49(1-2):161-165. https://doi.org/10.1016/j.clinbiochem.2015.09.011
        5.
        Chace DH, Kalas TA, Naylor EW. 2003. Use of Tandem Mass Spectrometry for Multianalyte Screening of Dried Blood Specimens from Newborns. 49(11):1797-1817. https://doi.org/10.1373/clinchem.2003.022178
        6.
        Newborn Screening Quality Assurance Program 2020 Quality Control Report. June 1, 2020. [Internet]. Available from: https://www.cdc.gov/labstandards/pdf/nsqap/QC_Report_S1_2020-508.pdf
        Sign In To Continue

        To continue reading please sign in or create an account.

        Don't Have An Account?